Geode Capital Management’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-167,216
| Closed | -$496K | – | 4084 |
|
|
2016
Q3 | $496K | Buy |
167,216
+77
| +0% | +$133 | ﹤0.01% | 3251 |
|
|
2016
Q2 | $249K | Sell |
167,139
-54,545
| -25% | -$125K | ﹤0.01% | 3504 |
|
|
2016
Q1 | $819 | Buy |
221,684
+46,552
| +27% | +$288K | ﹤0.01% | 2993 |
|
|
2015
Q4 | $1.77M | Buy |
175,132
+1,477
| +0.9% | +$17.8K | ﹤0.01% | 2560 |
|
|
2015
Q3 | $2.36M | Buy |
173,655
+7,109
| +4% | +$127K | ﹤0.01% | 2339 |
|
|
2015
Q2 | $3.16M | Sell |
166,546
-1,021
| -0.6% | -$22.1K | ﹤0.01% | 2215 |
|
|
2015
Q1 | $4.38M | Buy |
167,567
+13,179
| +9% | +$335K | ﹤0.01% | 1933 |
|
|
2014
Q4 | $3.23M | Sell |
154,388
-990
| -0.6% | -$24.9K | ﹤0.01% | 2103 |
|
|
2014
Q3 | $5.19M | Buy |
155,378
+9,958
| +7% | +$309K | ﹤0.01% | 1747 |
|
|
2014
Q2 | $4.67M | Buy |
145,420
+5,180
| +4% | +$193K | ﹤0.01% | 1832 |
|
|
2014
Q1 | $6.47M | Buy |
140,240
+11,188
| +9% | +$656K | ﹤0.01% | 1581 |
|
|
2013
Q4 | $9.16M | Sell |
129,052
-3,858
| -3% | -$295K | 0.01% | 1245 |
|
|
2013
Q3 | $11.4M | Buy |
132,910
+56,207
| +73% | +$4.76M | 0.01% | 978 |
|
|
2013
Q2 | $4.86M | Buy |
+76,703
| New | +$4.07M | ﹤0.01% | 1435 |
|
Geode Capital Management's AEGR Position: Q4 2016 in Review
Geode Capital Management sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 167,216 shares — an estimated $496K sold.
Geode Capital Management first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $11.4M in Q3 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- Geode Capital Management reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- Geode Capital Management sold 167,216 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $496K.
- Geode Capital Management first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
- Geode Capital Management's Aegerion Pharmaceuticals position peaked at $11.4M in Q3 2013.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on Geode Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.